VIVORYON THERAPEUTICS N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.753 EUR | -5.88% |
|
+32.11% | -90.75% |
| Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
| Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
| Sales 2023 | -3.62K -3.87K | Sales 2024 * | - | Capitalization | 20.85M 22.32M |
|---|---|---|---|---|---|
| Net income 2023 | -28M -29.97M | Net income 2024 * | -18M -19.27M | EV / Sales 2023 | -53,497 x |
| Net cash position 2023 | 18.52M 19.83M | Net cash position 2024 * | 19.55M 20.93M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.12
x | Employees | 15 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics N.V.
More press releases
| 1 day | -5.00% | ||
| 1 week | +33.33% | ||
| Current month | +40.74% | ||
| 1 month | +45.04% | ||
| 3 months | -91.70% | ||
| 6 months | -90.10% | ||
| Current year | -90.66% |
1 week
0.61
1.00
1 month
0.411.00
Current year
0.419.93
1 year
0.4119.56
3 years
0.4123.25
5 years
0.4123.25
10 years
0.4127.73
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.753 | -5.88% | 425 381 |
| 24-04-26 | 0.8 | -2.44% | 344,230 |
| 24-04-25 | 0.82 | -8.38% | 1,589,391 |
| 24-04-24 | 0.895 | +24.31% | 3,324,608 |
| 24-04-23 | 0.72 | +26.32% | 2,581,230 |
Real-time Euronext Amsterdam, April 29, 2024 at 10:31 am EDT
More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
2024-06-11
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.8
EUR
Average target price
41.57
EUR
Spread / Average Target
+5,095.83%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -90.66% | 22.26M | |
| +2.57% | 42.75B | |
| +47.81% | 41.61B | |
| +12.25% | 41.34B | |
| -12.36% | 26.59B | |
| +8.46% | 25.49B | |
| -23.33% | 18.12B | |
| +30.65% | 12.24B | |
| -1.58% | 11.76B | |
| +7.99% | 11B |
- Stock Market
- Equities
- VVY Stock
